Abstract
BackgroundRituximab (Rtx), a monoclonal antibody against CD20+, induces transient depletion of B cells and was approved for the treatment of patients with active rheumatoid arthritis (RA). Previous data1 showed that...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
